August 9, 2024 01:29 PM EDT

Genentech, Gilead push FDA to modernize research inspections

Zachary Brennan

Senior Editor

Roche’s Genentech, Gilead, Sanofi and other drugmakers weighed in on the FDA’s recent draft guidance on research inspections, with the companies calling for clarity and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genentech, Gilead push FDA to modernize research inspections

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Upstream Bio files for IPO in sign of life for biotech public offerings

Edgewise’s stock surges as heart drug passes early safety test

Breaking down silos with a new quantitative approach to drug development

Genen­tech, Gilead push FDA to mod­ern­ize re­search in­spec­tions

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Genentech, Gilead push FDA to modernize research inspections